Stifel lowered the firm’s price target on Outset Medical (OM) to $6 from $8 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OM:
- Outset Medical reports Q1 EPS ($1.03), consensus (79c)
- Outset Medical backs FY26 revenue view $125M-$130M, consensus $126.77M
- AI Models Turn Cautiously More Positive on Outset Medical as Turnaround Takes Shape
- Outset Medical: Tablo Platform’s System‑Wide Insights Drive Strategic Health System Adoption and Support Buy Rating